UK called to support proposal to waive patent protection for COVID-19 vaccines
The US and World Trade Organization have already expressed support for the initiative
Company
Pfizer Inc
NYSE:PFE
Pfizer Inc is a research-based biopharmaceutical company. The company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1.
293 stories · page 2 of 3
Moderna, Pfizer drop after US backs proposal to lift patent protection for COVID-19 vaccines to boost supply
It was first put forward by India and South Africa and is also supported by the WTO
Pfizer expects to make US$26bn annual revenues from COVID-19 vaccine
In the first quarter, vaccine revenues were US$3.5bn because the firm has been selling it for a profit, unlike other competitors
Archive
US stocks end mixed session marked by a sell-off in Big Tech stocks
Investors got spooked by a mix of concerns about rising inflation, fears the Fed may have to pull back monetary stimulus earlier than thought, and the potential for tax increases
Coronavirus: Pfizer/BioNTech vaccine works on Brazil variant, study shows
Scientists took blood samples from people who had already received the jab and analysed it against a lab-made reconstruction of the virus
Archive
Wall Street ends on mixed footing as big tech outperforms the Dow
IBM and salesforce shares did their part to drag down the blue chip index, losing nearly 3% and more than 6%, respectively.
Archive
"Real world" test of Pfizer COVID-19 vaccine in Israel determines effectiveness in preventing illness
A real-world test of Pfizer’s COVID-19 vaccine in more than half a million people confirms that it’s very effective at preventing serious illness or death, even after one dose. Wednesday’s published results, from a mass vaccination campaign
Archive
Precious Metals: Easy come's "But for how long will easy stay"
Most major miners are now very reluctant to embark on ambitious exploration and development programs. They have been punished by the markets for doing so for over the decade and are often described as capital destroyers. Instead, they have
Archive
Dow Jones climbs to record close on coronavirus vaccine and economic stimulus benefit hopes
The Dow Jones Industrials Average ended Wednesday up nearly 74 points, or 0.2%, at 30,409.6, its highest closing mark ever
Archive
Dow hits record intraday high after Trump signs off on $2.3 trillion spending package
Naeem Aslam, chief market analyst at Avatrade commented: “Traders are pleased that President Trump has finally given up on his demand (to increase the stimulus cheque payment to $2,000), and he has signed the coronavirus aid package bill"
Archive
Oil price, JOG, Chariot, PetroTal, BPC. And finally…
Oil remains quietly firm, last week WTI rose by 31c and Brent by 72c and both are up c.50 cents this morning taking the latter up over 50 bucks again, but drifts in early afternoon trading. The situation remains the same, whilst virus numbe
Archive
US stocks end mixed session as investors fret additional COVID-19 restrictions
New York City Mayor Bill De Blasio's warning of a "full shutdown" came as the US began to roll out a coronavirus vaccine designed by Pfizer and BioNTech to hundreds of distribution centers across the country
Coronavirus: UK plans to test combination of different jabs as Pfizer/BioNTech vaccine rollout starts
The studies would only involve approved jabs so they will be implemented once the Oxford vaccine receives the green light
Coronavirus: UK may implement new lockdown in January despite vaccine rollout, says JP Morgan
The country has seen a rise in infections last week despite having just ended a month-long lockdown
Coronavirus: UK to start vaccine rollout next week with 800,000 doses
It is not clear how many doses will be delivered to the UK by the end of the year
Pfizer/BioNTech to deliver 50mln doses of COVID-19 vaccine worldwide this month
The UK was the first to approve the jab and has secured 40mln doses but will not receive them all by the end of 2020
Archive
US stocks end mixed session after S&P 500 and Nasdaq Composite hit record highs
The Dow gained more than 11% in November, notching its best one-month performance since January 1987 as the S&P 500 and Nasdaq rose 10.8% and 11.8%, respectively
Archive
Oil price, Genel, Zephyr, Kistos, Echo, UOG. And finally…
Oil dithers waiting for tomorrow’s Opec+ meeting at which extending the 2m b/d production is in my view in the price, anything else would create uncertainty. Markets in general have rallied on the back of better international economic data
Coronavirus: UK first country to approve Pfizer/BioNTech vaccine
The rollout will begin next week and the first segments to receive it will be care home residents, health and care staff, the elderly and the clinically extremely vulnerable
Coronavirus: UK expected to approve Pfizer/BioNTech vaccine this week, acquires 2mln extra doses of Moderna jab
London is speeding up the processes to distribute the jabs, including bypassing EU authorities to issue an emergency authorisation
Archive
US stocks close higher on vaccine optimism as Biden taps ex-Fed Chair Yellen as Treasury secretary
Yellen headed the Fed from 2014 to 2018 when the S&P 500 rose nearly 60%
Pfizer, Moderna COVID-19 vaccine candidates may get EU approval in December
Pfizer and BioNTech have submitted an application to the US authorities for emergency approval on Friday
BetterLife says its AP-003 coronavirus treatment has similarities with Pfizer's vaccine
AP-003 and the Pfizer vaccine both utilize interferons, which are a natural part of the body’s innate immune system but that are blocked by the coronavirus
Pfizer now says COVID-19 vaccine is 95% effective and can be ready in days
On Monday, rival Moderna released data showing its rival candidate had achieved 94.5% effectiveness
Archive
US stocks close down sharply after sell-off in final minutes amid rising coronavirus cases
Stocks tanked despite Pfizer's announcement Wednesday that its vaccine was 95% effective in preventing COVID-19
Archive
FTSE 100 closes higher as vaccine hopes continue to cheer; sterling firms
Britain's blue-chip benchmark closed ahead by nearly 20 points at 6,385, while FTSE 250 added over 183 points at 19,699
Moderna’s COVID-19 vaccine candidate can be stored at warmer temperatures than Pfizer’s, easing distribution
The ultra-cold temperatures needed by Pfizer's jab may be a significant hurdle for its distribution
Oil rallies on vaccine hopes but demand seen continuing to fall for rest of year
In Friday trading, Brent crude was above US$43 with WTI over US$40 a barrel
Stock rotation after Pfizer’s positive vaccine news may have gone too far
The world is likely to need diagnostics and treatment for many more months, even after jabs start to be rolled out
Coronavirus: Russia says Sputnik V vaccine effective in 92% of cases
The Kremlin is planning to roll out the jab in the coming weeks
Malcy's Blog - Far Limited and Jadestone Energy
Far Limited (ASX:FAR) Far has announced a SPA with ONGC for their PSC offshore Senegal for $45m plus working cap since 1 Jan of $66.58m. The offer, whilst looking lower than might have been expected a while ago ‘represents the best option a
Archive
US stocks close mixed session as investors rotate out of technology and stay-at-home stocks
Investors are shifting into cyclical stocks that benefit from a recovering economy
Archive
Today's Market View - Bushveld Minerals; Endeavour Mining; Thor Mining and more...
Economics China – Credit growth slowed in October reflecting lower issuance of government bonds and seasonal factors in October as businesses were shut because of public holidays. Aggregate Financing (CNY bn): 1,420 v 3,477 in September and
Which Covid vaccine candidates are competing against Pfizer?
The US firm and partner BioNTech are just about to submit their jab to the US authorities. Who else is almost there?
Pfizer to submit COVID-19 vaccine candidate for emergency use authorisation next week after positive late-stage trial data
The jab was found to be effective in over 90% of cases while there were no safety concerns
Archive
Dow closes up more than 800 points on vaccine news, Biden win
Earlier today, Pfizer reported its vaccine candidate was 90% effective in phase III clinical trials, sending market sentiment sky high
Pfizer hopes to produce 100mln COVID-19 vaccine doses before 2021
The candidate is expected to be ready for submission to the authorities in the third week of November
Archive
US stocks end mixed as DJIA notches first daily gain in four sessions on strong US consumer data
The data showed US retail sales rose 1.9% month, well ahead of estimates of around 0.6%
Archive
US stocks close sharply lower after Trump calls off stimulus talks until after the election
The airlines are under pressure as the industry is hinging on additional aid to avoid more layoffs
Pfizer reports moderate side effects in COVID-19 vaccine trials
The independent data monitoring committee reviewing the study did not express safety concerns
Covid update: Pfizer says it will have the ability to supply 1.3bn vaccine doses by the end of next year (if trials and approvals go to plan)
The update was provided in after-hours data reveal by the pharma giant and its partner BioNTech SE
Archive
Wall Street overcomes early deficits to finish the week strong
Wall Street shares closed higher on Friday as Apple shares climbed
Pfizer coronavirus vaccine passes early stage trials
Regulatory review for the candidate is sought as early as October
Archive
FTSE 100 index keeps head above water as traders mull "plethora of risks"
Britain's top share index finished up around four points at 6,211 on the day
Pfizer and BioNTech land US$1.95bn COVID-19 vaccine order from US Government
The deal is for the first 100mln vaccine doses and can be expanded by a further 500mln doses – meanwhile, the clinical trial process continues to advance.
UK government orders 30mln doses of Pfizer and BioNTech COVID-19 vaccine
Pfizer and BioNTech said they expect to start a Phase 2b/3 safety and efficacy trial later this month and seek regulatory review as early as October.
Coronavirus: Pfizer, BioNTech get two vaccine candidates fast-tracked by US authorities
The two formulations showed positive results in early-stage trial data
Pfizer and BioNTech shares jump as early data from coronavirus vaccine trial cheers investors
It was reported that 24 people who received two doses of the vaccine had 'significantly elevated' antibodies within four weeks of the first injection
Pfizer’s coronavirus vaccine candidate enters first phase of US trials
The start of the US trial follows the first jabs administered in Germany last week
How much should a ‘blockbuster’ drug earn now?
While the term for a drug generating US$1bn in turnover has been around since the 1980s, three and a half decades of inflation since then means the sum doesn't go as far as it used to
Pfizer stock climbs as drug giant raises 2019 guidance
The New York drug maker now expects full-year revenue of between $51.2 billion and $52.2 billion
Medexus Pharmaceuticals adds veteran pharma executive to its board
The specialty pharmaceutical company says Adele Gulfo’s addition enhances the board’s commercial and business development expertise
Morgan Stanley doesn’t think there’s much money to be made by investing in GSK
GSK is in the middle of some big changes: it is bedding in a multi-billion-dollar acquisition; rebuilding its drugs pipeline; and merging its consumer healthcare division with one of its rivals
CytoDyn announces two new additions to management team
The company named Brendan Rae as senior vice president of business development and George Bitar as executive director, head of quality
CytoDyn's flagship drug leronlimab to be tested to prevent fatty liver diease in mice
The goal of the exploratory pre-clinical studies are to establish leronlimab’s ability to prevent the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) into NASH
Pharma stocks head south as Trump forces them to display drug prices in TV ads
“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”
ChemioCare taps retired Pfizer exec to its board
Roy Waldron joins the biotech company's board after recently retiring from Pfizer, where he spent nearly 20 years
CytoDyn presses forward with HIV treatment after Phase 3
Leronlimab is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Humanigen CEO optimistic on drug candidate after pulling company from the brink
The biotech is in the early stages of work on a drug designed to reduce the sometimes dangerous side effects of a cancer therapy involving altered T cells
Zynerba Pharmaceuticals adds pharma exec to its board
Pamela Stephenson brings expertise in commercial planning to the developer of transdermal cannabinoid therapies
Archive
LATE MOVERS: Symantec shares surge on the back of strong earnings results
Mellanox Technologies, the Israeli-based computer group also saw shares rise continue to rise on Thursday
CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial
Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
LATE MOVERS: Apple rallies after posting 1Q earnings that beat analysts' estimates
eBay advanced after hours as the online auction company beat estimates for quarterly sales thanks to a busy holiday period
GSK chairman steps down after consumer healthcare merger with Pfizer
GSK chairman Sir Philip Hampton said following a deal with Pfizer to merge their consumer businesses, he believes "this is the right moment" to step down
Investments and investor services
EARLY MOVERS: FedEx stock sinks as Trump's trade wars bite
Chipmaker says global glut in semiconductor supplies to hit earnings
GlaxoSmithKline spikes higher as it inks US$12.7bn consumer healthcare deal with Pfizer
GSK will own 68% of the combined entity, which brings together products such as Panadol and Advil
IPO Roundup: Non-opioid pain treatment developer Centrexion Therapeutics set to IPO
The Massachusetts-based biopharma is led by former Pfizer CEO Jeffrey B. Kindler
GlaxoSmithKline releases upbeat injectable HIV treatment results
Trials for ViiV Healthcare's once-a-month injection show it is as effective as the current standard of care for HIV patients
Pfizer narrows full year guidance as third quarter earnings beat forecasts but revenues disappoint
"We believe we are well-positioned to develop and commercialize differentiated new medicines, creating sustainable value for shareholders and patients," said Pfizer boss Ian Read.
EARLY MOVERS: Pfizer in focus pre-market as plans emerge to cut around 2% of global workforce; Endocyte leaps on Novartis deal
The billionaire owner of Golden Nugget Casinos Tilman Fertitta wants to do a deal with Caesars Entertainment Corp
Archive
EARLY MOVERS: General Electric has a power surge on CEO news; while Tesla puts pedal to metal too
Also in the frame in pre-market with more boardroom news was Pfizer Inc..
Investments and investor services
Exact Sciences stock surges on report of marketing collaboration with Pfizer
The two companies will co-promote the cancer screening test in fourth quarter of 2018
FTSE 100 closes higher as hopes grow for US, China trade talks
FTSE 100 closed ahead as the new trading week began, but off the 7,600 level, adding over 32 points to 7,591
Antares misses on earnings, but deal with Pfizer bolsters outlook
Market is focused on deal between Antares and Pfizer and ignoring a miss on earnings per share
Wall Street finishes July on a high note, led by Illumina, Pfizer
In Toronto, the TSX pushed about 86 points higher to close at 16,431.
Pfizer 2Q earnings beat Street on higher sales of Prevnar vaccine, arthritis drug Xeljanz
The New York drug giant boosted its full-year profit forecast, but trimmed its sales forecast warning that weakening currencies in Europe, Asia could nick revenue
Leap Therapeutics reveals new cancer drug trial collaboration with Merck KGaA and Pfizer
Phase 1/2 clinical trial to see whether TRX518, avelumab and chemotherapy shrinks advanced tumors in patients with relapsed or refractory ovarian, breast and prostate cancers
PRE-MARKET MOVERS: Fastenal fires up in pre-market after earnings top estimates, while Pfizer fizzes higher too
Also in play in pre-market is Morgan Stanley and its promotion and retailer Macy's..
PRE-MARKET MOVERS: Pfizer shares pick up in pre-market deals while PepsiCo peps up too
Also in the frame in pre-market was Lowe's Companies Inc and J M Smucker Co
Avacta Group appoints Immunocore’s Eliot Forster as non-executive chairman
The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director
Investments and investor services
IPO Roundup: Fintech lender GreenSky, 7 more companies pricing shares this week
Online lender GreenSky offers quick decisions on home improvement loans and will trade on Nasdaq with ticker 'GSKY'
Pfizer 1Q revenue misses analyst estimates as sales of Ibrance, Xeljanz disappoint
Drug giant also was dinged by loss last December of exclusivity of Viagra in the US
Investments and investor services
Dow falls on broad pullback, but tech rally keeps Nasdaq positive
Generally speaking, it has been a good earnings season so far for US companies, but a couple of disappointing announcements have scared investors who are already a little twitchy
Shires shares spike 4% after Takeda revises £43bn bid
Has the Japanese drugs giant sweetened further the cash element of its £43bn offer?
Shire: Takeda deadline looms, but will other bidders emerge for in-play £43bn drugs group?
Next week we'll see the colour of Takeda's money. Will rival bidders emerge from the woodwork?
Reckitt Benckiser shares drop as organic revenue growth misses expectations
Reckitt Benckiser reported a 2% increase in like-for-like revenue in the first quarter
Archive
Strong cold and flu season to boost Reckitt Benckiser sales in first quarter
Reckitt Benckiser will report organic sales growth of 2.8% in the first quarter, UBS estimates
Archive
High street issues to the fore as Debenhams, JD Sports, and Primark owner AB Foods provide updates
Week Ahead includes trading statements from Primark owner Associated British Foods, Debenhams, and JD Sports, plus Q1 numbers from Unilever, Reckitt Benckiser and Rentokil Initial
Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker
New York pharma giant is also working with Harvard researchers to develop fibrotic disease treatments
Respiri lifts $3 million to launch second-generation asthma management device
AirSonea device connects to a smartphone app to detect and measure wheeze.
Botanix Pharmaceuticals advances eczema study faster than expected
The company is developing BTX 1204, a new treatment for eczema.
Pfizer is in talks to sell consumer unit including Chapstick to Proctor & Gamble, says CNBC
Deal would include Chapstick lip balm and Centrum vitamins
GSK buys out consumer healthcare venture partner Novartis for US$13bn
The news comes just days after GSK bowed out of the race to take over the consumer healthcare unit of Pfizer
US stocks close lower, extending losses as US-China trade war worries gather pace
Spending bill signed by Trump failed to lift market sentiment
Nike Inc, Micron Technology, Cisco Systems, Pfizer and more - PRE-MARKET
After a sharp plunge in the markets on Thursday, Proactive takes a pre-market peek into the movers and shakers in New York
Reckitt clears way for GSK to buy Pfizer's consumer healthcare unit after ending talks
“An acquisition for the whole Pfizer consumer health business did not fit our acquisition criteria," said Reckitt boss Rakesh Kapoor
Biogen to buy schizophrenia drug from Pfizer for up to US$590mln
PF-04958242 helps the central nervous system to send and receive ‘messages’, and Biogen is looking to take it through Phase IIb trials later this year
Reckitt Benckiser's bid to buy Pfizer unit a step in the right direction, says JP Morgan
Shares in Reckitt have continued to decline after Monday's disappointing results as JP Morgan cut its 2018 earnings guidance and target price
Reckitt Benckiser Group expects a return to growth this year
The group returned to like-for-like revenue growth in the fourth quarter..
Apricus goes flat as FDA refuses to approve erectile dysfunction treatment
It’s the second time regulators have given the thumbs-down to Vitaros, with the FDA flagging concerns over one of the ingredients in the cream as well as with the manufacturing process